Eli Lilly profitiert von Novartis-Zukauf und neuen Produkten

Eli Lilly profitiert von Novartis-Zukauf und neuen Produkten


(dpa-AFX) Der US-Pharmakonzern Eli Lilly hat dank des Zukaufs der Novartis-Sparte für Tiermedizin beim Umsatz im vierten Quartal zugelegt. Die Erlösen kletterten um fünf Prozent auf 5,38 Milliarden US-Dollar, wie das Unternehmen in Indianapolis mitteilte. Ohne Währungseffekte durch den starken Dolla...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Johnson & Johnson (JNJ) Shares Bought by Armstrong Henry H Associates Inc.

Johnson & Johnson (JNJ) Shares Bought by Armstrong Henry H Associates Inc.


Armstrong Henry H Associates Inc. raised its position in Johnson & Johnson by 1.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission . The firm owned 488,609 shares of the company's stock after buying an additional 5,222 shares during the period.



from Biotech News
Share:

Atlas Brown Inc. Has $457,000 Position in Merck & Co., Inc.

Atlas Brown Inc. Has $457,000 Position in Merck & Co., Inc.


Atlas Brown Inc. reduced its position in shares of Merck & Co., Inc. by 5.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 9,074 shares of the company's stock after selling 528 shares during the period.



from Biotech News
Share:

Six people being tested for Zika virus in Bexar County

Six people being tested for Zika virus in Bexar County


This 2006 photo provided by the Centers for Disease Control and Prevention shows a female Aedes aegypti mosquito in the process of acquiring a blood meal from a human host. On Friday, Jan. 15, 2016, U.S. health officials are telling pregnant women to avoid travel to Latin America and Caribbean countries with outbreaks of a tropical illness linked to birth defects.



from Biotech News
Share:

26,193 Shares in Biogen Inc (BIIB) Acquired by Accident Compensation Corp

26,193 Shares in Biogen Inc (BIIB) Acquired by Accident Compensation Corp


Accident Compensation Corp bought a new stake in shares of Biogen Inc during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 26,193 shares of the biotechnology company's stock, valued at approximately $8,024,000.



from Biotech News
Share:

Among high risk kids, both boys and girls are victims of dating violence

Among high risk kids, both boys and girls are victims of dating violence


For kids and teens exposed to violence at home or in the community, boys are just as likely to be seriously hurt by a romantic partner, although the risk changes with age, according to a new study. "Most samples are not specifically high risk populations where youth are previously exposed to violence," said lead author Dennis E. Reidy of the Division of Violence Prevention at the Centers for Disease Control and Prevention in Atlanta.



from Biotech News
Share:

Ga. Police Chase Ends In Deaths, Drug Trafficking Charges

Ga. Police Chase Ends In Deaths, Drug Trafficking Charges


A father and son from Mosheim face multiple charges following a traffic crash Thursday night in Gwinnett County, Ga., that killed the occupants of the other vehicle. Larry Edward Thomas, 47, of 580 Bewley Road, was driving a Ford Crown Victoria sedan that collided with a Mercedes in Gwinnett County as it was being pursued by a Johns Creek Police Department officer from neighboring Fulton County, according to a news release from the Gwinett County Police Department.



from Biotech News
Share:

What To Buy In This Biotech Sell-Off

What To Buy In This Biotech Sell-Off


I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it .



from Biotech News
Share:

State confirms 3 SC residents tested for Zika virus

State confirms 3 SC residents tested for Zika virus


Health officials say three people in South Carolina are being tested for the Zika virus, but no cases of the disease have been confirmed yet. Department official Dr. Teresa Foo tells local media that the chances of getting Zika virus in South Carolina are minuscule.



from Biotech News
Share:

Gilead: Detailed Insight And Interpretation Behind The Headlines: Should You Be Scared?

Gilead: Detailed Insight And Interpretation Behind The Headlines: Should You Be Scared?


I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it .



from Biotech News
Share:

Hillary, Don't Attack Valeant, Attack Lawmakers

Hillary, Don't Attack Valeant, Attack Lawmakers


I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it .



from Biotech News
Share:

Danbury-based firm lays off half its staffers

Danbury-based firm lays off half its staffers


Danbury-based pharmaceutical developer Biodel has laid off 15 people, more than half of its workforce, after a crumbled partnership forced it to suspend a drug trial and evaluate options including a sale or a reverse merger, in which another company would acquire Biodel for its Nasdaq listing and cash reserves. It would amount to an ignominious end for Biodel, created in 2003 by onetime MannKind executive Dr. Solomon Steiner and others who set out initially to develop VIAject, an insulin treatment for diabetics designed to be absorbed into the blood faster than alternatives at the time, with a later version of the technology called Linjeta.



from Biotech News
Share:

More airlines offer Zika refunds to pregnant women

More airlines offer Zika refunds to pregnant women


Doctor Angela Rocha shows brain scans of a baby born with microcephaly at the Oswaldo Cruz Hospital in Recife, Brazil, Thursday, Jan. 28, 2016. Brazilian officials still say they believe there's a sharp increase in cases of microcephaly and strongly suspect the Zika virus, which first appeared in the country last year, is to blame.



from Biotech News
Share:

FDA OKs Merck hepatitis C drug, adding to patient choices

FDA OKs Merck hepatitis C drug, adding to patient choices


Patients with hepatitis C have yet another advanced treatment option, as the Food and Drug Administration on Thursday approved a new once-a-day pill developed by drugmaker Merck. The FDA said Merck can begin marketing Zepatier for patients with two of the subtypes the liver-destroying virus, types 1 and 4. The combination pill includes the medications elbasvir and grazoprevir, which attack the virus in two different ways.



from Biotech News
Share:

Amgen trounces Street views with 39 pct. jump in 4Q profit

Amgen trounces Street views with 39 pct. jump in 4Q profit


This Nov. 9, 2014, file photo, shows signage outside the Amgen headquarters in Thousand Oaks, Calif. Amgen Inc. reports financial results on Thursday, Jan. 28, 2016.



from Biotech News
Share:

Late run sees ASX finish on a high

Late run sees ASX finish on a high


The Australian share market has raced home on a high note after enduring a fitful session of ups and downs. A strong late run from the big four banks helped steer the bourse out of the red after it was weaker for most of trade.



from Biotech News
Share:

Records: Site had proper procedures before listeria outbreak

Records: Site had proper procedures before listeria outbreak


A newspaper says inspection records show that a southwestern Ohio facility that produced packaged salads linked to a listeria outbreak had proper procedures in place in recent years to prevent illness. The Centers for Disease Control and Prevention said last week it linked the six-state outbreak to Dole salads this month after Ohio agriculture officials found listeria in a bag bought at a retail location.



from Biotech News
Share:

Roche blickt optimistisch in die Zukunft

Roche blickt optimistisch in die Zukunft


(dpa-AFX) Der Schweizer Pharmakonzern Roche sieht dank aussichtsreicher Medikamentenentwicklungen vorsichtig optimistisch in die Zukunft. 2016 dürfte es moderate Umsatzsteigerungen geben, der betriebliche Kerngewinn soll etwas stärker wachsen. Währungseffekte klammert das Unternehmen jedoch aus. Der...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Obama creates new federal task force on cancer

Obama creates new federal task force on cancer


Obama signed a presidential memo Thursday establishing the White House Cancer Moonshot Task Force. The memo says the goal is to double the rate of progress on treatment and prevention.



from Biotech News
Share:

Stamford audio giant drops after bell

Stamford audio giant drops after bell


On January 25, 2016, Harman International Industries held the official opening of its new North American automotive headquarters in Novi, Mich., with the company employing 1,000 people inside the 190,000-square-foot center in Haggerty Corridor Corporate Park. On January 25, 2016, Harman International Industries held the official opening of its new North American automotive headquarters in Novi, Mich., with the company employing 1,000 people inside the ... more Shares of Harman International Industries fell 6 percent in early trading Thursdsay, after the Stamford-based company reported a drop in earnings for its second fiscal quarter compared to a year earlier.



from Biotech News
Share:

Bristol-Myers posts 4Q loss, but beats views as sales rise

Bristol-Myers posts 4Q loss, but beats views as sales rise


Bristol-Myers Squibb Co. swung from a tiny profit to a loss in the fourth quarter as it fought multiple headwinds, but it still beat Wall Street expectations.



from Biotech News
Share:

IBM: Will Big Data Analytics + Big Pharma = Big Profits?

IBM: Will Big Data Analytics + Big Pharma = Big Profits?


I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. What if everyone's health history was recorded and analyzed? What could be done with this information to improve treatment regimens or develop new medicines? A couple of recent pairings are working to answer these questions.



from Biotech News
Share:

Regeneron wants to build a second East Greenbush campus

Regeneron wants to build a second East Greenbush campus


Regeneron submitted this site plan for a second campus it wants to build neat Exit 9 on Interstate 90. The campus would have 1,500 parking spaces when completed. It would have office, lab, warehouse and manufacturing space.



from Biotech News
Share:

3 Must Own Biotech Stocks For February

3 Must Own Biotech Stocks For February


The biotech sector has been in an official bear market for some time and is down some 30% since its recent peak in mid-summer. Bargains abound for patient long-term investors.



from Biotech News
Share:

Massachusetts is investigating high cost of hepatitis C drug

Massachusetts is investigating high cost of hepatitis C drug


The Massachusetts attorney general's office is investigating whether the makers of a breakthrough treatment for hepatitis C are violating state law by pricing the drug too high. Attorney General Maura Healey on Wednesday released a letter sent to the chief executive of California-based Gilead Sciences Inc. In it, Healey said her office was examining whether the pricing constituted an unfair trade practice.



from Biotech News
Share:

Novartis geht für 2016 von starker Generika-Konkurrenz aus

Novartis geht für 2016 von starker Generika-Konkurrenz aus


(dpa-AFX) Der Schweizer Pharmakonzern Novartis geht für das laufende Jahr erneut von einer starken Konkurrenz durch Generika aus. Auch die Dollar-Stärke dürfte den Konzern weiter belasten. Wachstum in allen Sparten soll die Belastungen aber ausgleichen, so dass sich die Schweizer für 2016 Erlöse und...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Biogen 4Q profit falls on costs, but tops forecasts

Biogen 4Q profit falls on costs, but tops forecasts


In this Feb. 15, 2006, file photo, two women walk by Biogen Idec corporate headquarters in Cambridge, Mass. Biogen reports financial earnings Wednesday, Jan. 27, 2016.



from Biotech News
Share:

Things to know about the mosquito villain in Zika outbreaks

Things to know about the mosquito villain in Zika outbreaks


This 2006 photo provided by the Centers for Disease Control and Prevention shows a female Aedes aegypti mosquito in the process of acquiring a blood meal from a human host. Scientists believe the species originated in Africa, but came to the Americas on slave ships.



from Biotech News
Share:

Supergroup PLC's (SGP) "Hold" Rating Reaffirmed at Numis Securities Ltd

Supergroup PLC's (SGP) "Hold" Rating Reaffirmed at Numis Securities Ltd


's stock had its "hold" rating reissued by analysts at Numis Securities Ltd in a research note issued to investors on Wednesday, AnalystRatings.Net reports. They currently have a GBX 1,400 target price on the stock.



from Biotech News
Share:

United, American offering refunds for travel to Zika areas

United, American offering refunds for travel to Zika areas


American Airlines says it will give refunds to pregnant women who were planning to travel to parts of Central America. The U.S. Centers for Disease Control and Prevention have warned pregnant women to take precautions against mosquito bites when traveling to areas in Latin America and the Caribbean where there have been Zika outbreaks.



from Biotech News
Share:

The Latest: Virginia resident tests positive for Zika virus

The Latest: Virginia resident tests positive for Zika virus


The latest on the fight against the Zika virus that health officials suspect is linked to a wave of birth defects in Brazil. : Health officials say a Virginia resident who travelled outside the United States has tested positive for Zika, a mosquito-transmitted virus.



from Biotech News
Share:

ASHP Publishes Guide for Treating Obese Patients

ASHP Publishes Guide for Treating Obese Patients


A new publication from ASHP will help clinicians determine optimal medication doses for obese patients. Demystifying Drug Dosing in Obese Patients is the first text focused on dosing critical and narrow therapeutic index drugs in obese pediatric and adult patients. The publication provides an overview of dosing medications in obese patients and summarizes the available literature for dosing of antimicrobial agents, anticoagulant and antiplatelet drugs, antiepileptic, antineoplastic, and analgesic medications. The reference includes insight and recommendations from nationally recognized experts, including sample calculations and equations to help clinicians apply the literature to individual patients. “The sharp growth in obesity rates in the United States heightens the need for clear, evidence-based guidance,” says Brandon R. Shank, Pharm.D., BCOP, a co-editor of the text. “It is essential that clinicians have a thorough understanding of the complexities involved in making dosing decisions for obese patients. It is our hope that this guide depicts the existing literature in a way that allows practitioners to apply literature to real-life patient scenarios.”Demystifying Drug Dosing in Obese Patients also addresses the issues surrounding the dosing of obese pediatric, critical care, and organ transplant patients. The publication offers guidance on immunosuppression and medication absorption for patients who have undergone gastric bypass or other bariatric surgeries. The text explains the critical concepts of absorption, distribution, metabolism, and clearance, and it includes helpful tips for weight-based dosing, drug efficacy, dosing concentrations, and toxicity. Dr. Shank is a clinical pharmacy specialist at the University of Texas MD Anderson Cancer Center and adjunct clinical assistant professor at Texas Southern University. His practice area is inpatient and outpatient lymphoma, multiple myeloma, and stem cell transplantation. Co-editor David E. Zimmerman, Pharm.D., BCPS, is an assistant professor of pharmacy at the Mylan School of Pharmacy at Duquesne University and an emergency medicine clinical pharmacist at the University of Pittsburgh Medical Center-Mercy Hospital. He is published in the areas of emergency medicine and neurology and is involved in developing emergency medicine clinical pharmacy services outside of the United States. For more information on Demystifying Drug Dosing in Obese Patients, visit the ASHP Store. About ASHP

ASHP Health-System Pharmacy Press Releases and Announcements

Öffnungszeiten der Schufa

Share:

The Latest: US starts research into possible Zika vaccine

The Latest: US starts research into possible Zika vaccine


The latest on the fight against the Zika virus that health officials suspect is linked to a wave of birth defects in Brazil. : The U.S. government is beginning research into a possible vaccine for the mosquito-borne Zika virus that is suspected of causing an unusual birth defect as it spreads in Latin America.



from Biotech News
Share:

Oil fuels 'schizophrenic' Wall Street rebound

Oil fuels 'schizophrenic' Wall Street rebound


Wall Street rebounded over 1 percent on Tuesday, driven by a surge in oil prices and strong quarterly results from 3M, Johnson & Johnson and Procter & Gamble. All 10 major S&P sectors ended higher, led by a 3.78-percent rise in the energy sector.



from Biotech News
Share:

Morphosys erhält Meilensteinzahlung von Bayer

Morphosys erhält Meilensteinzahlung von Bayer


(dpa-AFX) Das Biotech-Unternehmen Morphosys hat für den Start einer Phase-2-Studie von dem Chemie- und Pharmakonzern Bayer eine Meilensteinzahlung erhalten. Ziel der Studie sei es, die Zulassung des Wirkstoffs Anetumab Ravtansine zu unterstützen, teilte Morphosys am Dienstag mit. Bei dem Wirkstoff h...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Big U.S. biotech profit reports could boost industry's swooning shares

Big U.S. biotech profit reports could boost industry's swooning shares


Biotech's biggest companies could help restore investor confidence in the beaten-up industry as they report quarterly results starting this week. Valuations suggest biotech shares could be closing in on a bottom, and some analysts said strong results could clear the way for potential buyers.



from Biotech News
Share:

Open-source Laser Fabrication Lowers Costs for Cancer Research

Open-source Laser Fabrication Lowers Costs for Cancer Research


In a move that slashes 90 percent of the cost of mass-producing metastatic microtumors and therapeutic microtissues for screening and research, Rice University bioengineers have adapted techniques from the "maker" movement to reprogram a commercial laser cutter to etch up to 50,000 tiny "microwells" per hour into sheets of silicone. The fabrication technique, which was developed with open-source software and hardware, is described in a new study published in the journal RSC Advances .



from Biotech News
Share:

Johnson & Johnson beats 4Q profit forecasts

Johnson & Johnson beats 4Q profit forecasts


In this Monday, July 16, 2012, file photo, Johnson & Johnson products are displayed in Orlando, Fla.



from Biotech News
Share:

Biotech Weekly: The NASDAQ Sub $10 Million Market Cap Club

Biotech Weekly: The NASDAQ Sub $10 Million Market Cap Club


Reasons to review the NASDAQ sub $10 million market cap list include the value of a NASDAQ listing, significant remaining assets, overly negative sentiment, and ignored upside scenarios. Current sub $10 million market cap NASDAQ biotechs include Cellectar Biosciences, Nanosphere, Lpath, Signal Genetics, Venaxis, TetraLogic Pharmaceuticals, Eleven Biotherapeutics, and GenVec.



from Biotech News
Share:

Biotech Deserves A Piece Of Every Dividend Growth Portfolio

Biotech Deserves A Piece Of Every Dividend Growth Portfolio


Taking into account their projected EPS growth rates and potential for dividend growth, both companies, but in particular Gilead Sciences, are attractively valued relative to the market. Amgen became a pioneer in the biotech world when it became the first large biotech stock to begin paying a regular dividend in 2011.



from Biotech News
Share:

Reasons to Expect Strong Bristol-Myers Earnings

Reasons to Expect Strong Bristol-Myers Earnings


Recent market volatility and global pressures have tempered investors' expectations for a strong earnings season, but not all companies will do poorly. Although Bristol-Myers Squibb shares -- down some 7% year to date -- is not off to a good start in 2016, the multinational drug giant belongs on any short list of companies poised to beat Wall Street's earnings estimates.



from Biotech News
Share:

Women advised to avoid pregnancy as Zika virus spreads

Women advised to avoid pregnancy as Zika virus spreads


Women advised to avoid pregnancy as Zika virus spreads In El Salvador, authorities have asked women not to get pregnant until 2018. Check out this story on WFAA.com: http://usat.ly/1RJho92 In the past year, Zika has spread from Africa and Asia through the Americas.



from Biotech News
Share:

Johnson & Johnson Earnings May Be Scrutinized For Deal Buzz, Product Snags

Johnson & Johnson Earnings May Be Scrutinized For Deal Buzz, Product Snags


On average, analysts reporting to Thomson Reuters are looking for JNJ earnings of $1.42 a share on top-line sales of $17.9 billion. Short-term option traders are looking for the earnings news to potentially generate a 2.5% move on the stock in either direction.



from Biotech News
Share:

European organic and biotech industries clash over plant breeding techniques

European organic and biotech industries clash over plant breeding techniques


"To me IFOAM's reaction is a bit of a Pavlov's dog reflex. If you dig a bit deeper you see that people look at these techniques in a differentiated way," said Garlich Von Essen of the European Seed Association.



from Biotech News
Share:

Democratic senator blocks Obama's pick to head FDA

Democratic senator blocks Obama's pick to head FDA


Massachusetts Sen. Edward Markey says in a statement that he's put a hold on Dr. Robert Califf's nomination. The Centers for Disease Control and Prevention says deaths linked to misuse and abuse of prescription painkillers climbed to 19,000 last year, the highest on record.



from Biotech News
Share:

Gilead Closes Galapagos Deal- Opens Up Massive Market Opportunity

Gilead Closes Galapagos Deal- Opens Up Massive Market Opportunity


I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it .



from Biotech News
Share:

Novavax Announces Proposed Offering of $200 Million of Convertible Senior Notes Due 2023

Novavax Announces Proposed Offering of $200 Million of Convertible Senior Notes Due 2023


Novavax, Inc. , a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that it intends to offer, subject to market and other conditions, $200 million aggregate principal amount of convertible senior unsecured notes that will mature on February 1, 2023 . The Notes will be offered and sold only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.



from Biotech News
Share:

GSK, Astra, J&J link with universities in new drug research fund

GSK, Astra, J&J link with universities in new drug research fund


GlaxoSmithKline, AstraZeneca and Johnson & Johnson have joined with three leading British universities to create a new 40 million pounds fund backing early drug research. The Apollo Therapeutics Fund, which aims to improve the speed and potential of university research being translated into new medicines, is a further example of a trend by Big Pharma to tap into academic science in the hunt for treatments.



from Biotech News
Share:

QLT Inc. (QLTI) Earns Hold Rating from Zacks Investment Research

QLT Inc. (QLTI) Earns Hold Rating from Zacks Investment Research


's stock had its "hold" rating reiterated by Zacks Investment Research in a report issued on Sunday, AnalystRatings.Net reports. They currently have a $3.00 target price on the stock.



from Biotech News
Share:

Opexa Therapeutics Inc (OPXA) Upgraded to "Buy" by Zacks Investment Research

Opexa Therapeutics Inc (OPXA) Upgraded to "Buy" by Zacks Investment Research


The firm presently has a $2.00 price target on the biopharmaceutical company's stock. Zacks Investment Research 's target price indicates a potential upside of 4.04% from the stock's current price.



from Biotech News
Share:

LDC und Roche wollen gemeinsam innovative Wirkstoffprojekte vorantreiben

LDC und Roche wollen gemeinsam innovative Wirkstoffprojekte vorantreiben


Die Lead Discovery Center GmbH (LDC) und Roche werden kooperieren, um innovative therapeutische Ansätze zu identifizieren und gemeinsam zu erforschen. Der Fokus liegt auf Krankheitsgebieten mit einem dringenden medizinischem Bedarf. Projektideen können sowohl von akademischen Partnern des LDC stamme...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

USC Eye Study Finds Near-Sightedness Growing

USC Eye Study Finds Near-Sightedness Growing


The largest study of childhood eye diseases undertaken in the U.S. confirms that the incidence of childhood myopia among American children has more than doubled over the last 50 years, USC and the National Institutes of Health announced Wednesday. The findings from the Multi-Ethnic Pediatric Eye Disease Study echo research among adults and children in Asia, where 90 percent or more of the population have been diagnosed with near-sightedness, up from 10 to 20 percent 60 years ago, according to Dr. Rohit Varma, and director of the USC Eye Institute at Keck Medicine at USC.



from Biotech News
Share:

ETF Update: 4 New Launches And 2 Closures

ETF Update: 4 New Launches And 2 Closures


I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. Every week, Seeking Alpha aggregates ETF updates in an effort to alert readers and contributors to changes in the market.



from Biotech News
Share:

Flint hospital suspected river, Legionnaires' outbreak link

Flint hospital suspected river, Legionnaires' outbreak link


Conor Ralph/The Flint Journal-MLive.com via AP Flint resident Grant Porter, 5, watches as his mother Ardis Porter, 26, has her blood drawn for lead testing at the Flint Masonic Temple on Saturday in Flint, Michigan. Porter said she was having her and her son tested because she's pregnant and he's young.



from Biotech News
Share:

Lenox Wealth Advisors Divests From Position in SPDR S&P Biotech

Lenox Wealth Advisors Divests From Position in SPDR S&P Biotech


Lenox Wealth Advisors sold its position in shares of SPDR S&P Biotech during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission . The firm previously had a 735 share position in the company, valued at approximately $145,831.



from Biotech News
Share:

Medical Marijuana Biotech Brands - Potbotics is a Biotech Startup...

Medical Marijuana Biotech Brands - Potbotics is a Biotech Startup...


Potbotics is a scientific cannabis startup that brings biotechnology into dispensaries everywhere. With what the brand describes as "diverse technology," Potbotics incorporates robotics, artificial intelligence, cannabis research and DNA analysis.



from Biotech News
Share:

Mitchell Sinkler & Starr Continues to Hold Position in Novartis AG

Mitchell Sinkler & Starr Continues to Hold Position in Novartis AG


Mitchell Sinkler & Starr held its stake in shares of Novartis AG during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The hedge fund owned 3,596 shares of the company's stock at the end of the fourth quarter.



from Biotech News
Share:

CBC retracts anti-supplements story based on faulty tests

CBC retracts anti-supplements story based on faulty tests


The Canadian Broadcasting Corporation has retracted a report it aired recently alleging spiking and missing ingredients in supplements because it was based on faulty test results. The report, aired on the CBC show Marketplace, alleged that Emergen-C, made by Pfizer, and and two protein powders, GNC Lean Shake 25 and Cytosport Muscle Milk, did not meet label claims.



from Biotech News
Share:

McKesson Co. (MCK) Position Held by Private Asset Management

McKesson Co. (MCK) Position Held by Private Asset Management


Private Asset Management held its position in McKesson Co. during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission .



from Biotech News
Share:

Amgen announces approval of cholesterol-lowering medication Repatha (evolocumab) Injection in Japan

Amgen announces approval of cholesterol-lowering medication Repatha (evolocumab) Injection in Japan


Amgen today announced that the Japanese Ministry of Health, Labour and Welfare has approved the cholesterol-lowering medication Repatha Injection, the first proprotein convertase subtilisin/kexin type 9 inhibitor to be approved in Japan. Repatha is a human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver's ability to remove low-density lipoprotein cholesterol , or "bad" cholesterol, from the blood.



from Biotech News
Share:

Galena Biopharma Inc (GALE) Receives "Outperform" Rating from Oppenheimer

Galena Biopharma Inc (GALE) Receives "Outperform" Rating from Oppenheimer


's stock had its "outperform" rating restated by equities research analysts at Oppenheimer in a research report issued to clients and investors on Friday, MarketBeat reports. They currently have a $4.00 price objective on the biotechnology company's stock.



from Biotech News
Share:

Is your skin scrub enviro-friendly? More companies agree not to use microbeads

Is your skin scrub enviro-friendly? More companies agree not to use microbeads


Eleven major companies have now agreed to phase out microbeads from face scrub cosmetic products since Fairfax Media first reported on the campaign by environmental activist Jon Dee more than a year ago. Mr Dee said that two more major companies, Johnson & Johnson and Metcash, owners of IGA supermarkets, had this week agreed to support the scheme.



from Biotech News
Share:

Health officials probe tie between Zika, paralyzing syndrome

Health officials probe tie between Zika, paralyzing syndrome


Health officials say they're trying to determine if an unusual jump in cases of the rare Guillain-Barre Syndrome is related to the spread of the mosquito-borne Zika virus in El Salvador. Fears the illness might cause birth defects already has led authorities in the Central American nation to warn women against becoming pregnant.



from Biotech News
Share:

1 dead in listeria outbreak linked to packaged lettuce

1 dead in listeria outbreak linked to packaged lettuce


Packaged salads produced at a Dole facility in Ohio are linked to one death in Michigan, the Centers for Disease Control and Prevention said Friday. The CDC said 12 people in six states have been hospitalized in the outbreak since July after eating salads sold under the names Dole, Fresh Selections, Simple Truth, Marketside, The Little Salad Bar and President's Choice.



from Biotech News
Share:

Astellas Pharma $8.50 Tender Offer For Ocata Therapeutics Offer Fails Again

Astellas Pharma $8.50 Tender Offer For Ocata Therapeutics Offer Fails Again


The ongoing battle for control of Ocata Therapeutics inched closer to completion today as an SEC filing reveals that 47% of outstanding shares have been tendered in response to the November 19, 2015 tender offer by Japan based Astellas Pharma to acquire the stem cell therapeutics company. This is the second extended tender deadline that has failed to achieve the required 50.1% shares despite an aggressive campaign by Ocata management to convince shareholders that the $360,000,000 tender offer is in the best interest of shareholders.



from Biotech News
Share:

Meningitis B vaccine shortage halts new private jabs

Meningitis B vaccine shortage halts new private jabs


Parents hoping to have their children vaccinated privately against meningitis B have been told there is a shortage of vaccine. But private clinics in the UK have been advising parents that they cannot start any new courses of the vaccine.



from Biotech News
Share:

MannKind Launches New Direction For Afrezza

MannKind Launches New Direction For Afrezza


MannKind Corporation's long-term CFO and newly chosen CEO, Matt Pfeffer, recently advanced a new blueprint at the J.P. Morgan Healthcare Conference, held two weeks ago, for the company's direction now that MannKind's partnership with Sanofi will be coming to an end.



from Biotech News
Share:

Zika virus likely to spread to southern United States

Zika virus likely to spread to southern United States


By Karen Pallarito HealthDay Reporter THURSDAY, Jan. 21, 2016 -- As cases of the mosquito-borne Zika virus are spreading across central and South America and the Caribbean, experts say it's only a matter of time before the disease, which has been linked to an alarming increase in birth defects in Brazil, is transmitted within the United States. "It's not if, it's when," said Mustapha Debboun, director of the mosquito control division at Harris County Public Health and Environmental Services in Houston.



from Biotech News
Share:

UPDATE 1-J&J stops trials of drug similar to one linked to brain death in France

UPDATE 1-J&J stops trials of drug similar to one linked to brain death in France


Jan 21 Johnson & Johnson has suspended international trials of a drug in the same class as an experimental drug made by Portuguese pharmaceutical company Bial, whose tests in France left one person brain dead and five others hospitalized. A spokesman for Johnson & Johnson said in an emailed statement that it voluntarily suspended two mid-stage trials and had not received reports of serious adverse events in its studies of patients with social anxiety disorder and major depressive disorder with anxious distress.



from Biotech News
Share:

An Increased Emphasis on "Proportional Discovery"

An Increased Emphasis on "Proportional Discovery"


Magistrate Judge Grewal has denied a motion to compel discovery because the requests were "disproportionate," alluding to the requirement in newly amended Rule 26 , F.R.Civ.P., that the discovery sought should be "proportional to the needs of the case." Gilead Sciences, Inc. v.



from Biotech News
Share:

Goldman Plans To Dominate M&A In 2016

Goldman Plans To Dominate M&A In 2016


Goldman Sachs dominated deal advisory for this strong M&A market last year and expects to do so again this year. In the fourth quarter, investment banking made up over 20% of the bank's revenue, up from 15% a few years before.



from Biotech News
Share:

Roche erhält für Leukämie-Medikament Breakthrough Therapy-Status

Roche erhält für Leukämie-Medikament Breakthrough Therapy-Status


(dpa-AFX) Roche hat von der US-Gesundheitsbehörde FDA für das Medikament Venetoclax in Kombination mit MabThera/Rituxan (Rituximab) von der US-Gesundheitsbehörde FDA den "Breakthrough Therapy"-Status erhalten. Das Leukämie-Medikament entwickelt die Roche-Tochter Genentech zusammen mit Abbvie. Das Mi...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

UPDATE 1-Five charged in U.S. with stealing secrets from GlaxoSmithKline

UPDATE 1-Five charged in U.S. with stealing secrets from GlaxoSmithKline


The indictments include charges of conspiracy to steal trade secrets, conspiracy to commit wire fraud, conspiracy to commit money laundering, theft of trade secrets, and wire fraud. The stolen information on drugs for cancer and other serious diseases "potentially could be sold for millions of dollars to rival pharmaceutical companies and it would also be useful information for a start-up pharmaceutical company," the complaint said.



from Biotech News
Share:

Five charged in US with trying to steal from pharma giant

Five charged in US with trying to steal from pharma giant


A US judge has charged five people with trying to steal trade secrets from the British pharmaceutical group GlaxoSmithKline . The indictment says the five suspects tried to steal secrets from the company's work in biopharmaceuticals, mainly in products to treat cancer and other grave diseases.



from Biotech News
Share:

The Latest: Austria calls for EU asylum reform

The Latest: Austria calls for EU asylum reform


Bracing cold temperatures hundreds of migrants continue to arrive daily into Serbia in order to register a... Schools would have more flexibility to serve refined grains and salty foods to the nation's school children under legislation a Senate panel is considering. The Supreme Court has rejected an appeal from the manufacturer of Children's Motrin over a $63 million judgment awarded to a family whose daughter developed a life-threatening disease after taking the medicine.



from Biotech News
Share:

5 charged in alleged scheme to steal drug secrets

5 charged in alleged scheme to steal drug secrets


Five people have been accused in federal court of taking part in an alleged scheme to steal biopharmaceutical trade secrets from GlaxoSmithKline and sell them to competitors in China. Charges in the indictment include conspiracy to steal trade secrets and conspiracy to commit wire fraud and money laundering.



from Biotech News
Share:

More

More


Two types of children's cough syrup sold at stores with outlets in Central Texas are being recalled after dosing cups with incorrect markings were included in the packaging. Experts say that could lead to accidental overdoses.



from Biotech News
Share:

Spreading Zika virus a new economic strain for Latin America

Spreading Zika virus a new economic strain for Latin America


A U.S. warning that pregnant women should avoid Latin American countries where a mosquito-borne virus is multiplying couldn't have come at a worse time for a region that's counting on tourism to give it a boost at a time of economic crises. The alert issued Friday by the Atlanta-based Centers for Disease Control and Prevention covers 14 countries and territories in the Americas where the Zika virus has been detected.



from Biotech News
Share:

Namenswechsel: Cytos Biotechnology wird zu Kuros Biosciences

Namenswechsel: Cytos Biotechnology wird zu Kuros Biosciences


Kuros Biosciences AG (vormals Cytos Biotechnology AG) hat den Vollzug der Akquisition von Kuros Biosurgery Holding AG sowie den Namenswechsel zu Kuros Biosciences AG bekannt gegeben. Ab dem 20. Januar 2016 sind sämtliche 508.432.244 Kuros Biosciences AG Aktien börsenkotiert unter dem Ticker Symbol K...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Johnson & Johnson baut Stellen ab

Johnson & Johnson baut Stellen ab


(dpa-AFX) Der US-Pharma- und Konsumgüterkonzern Johnson & Johnson (J&J) setzt in seinem Profi-Medizintechnik-Geschäft den Rotstift an. Rund 4 bis 6 Prozent der Mitarbeiter weltweit in diesem Bereich sollen dabei innerhalb von zwei Jahren ihren Posten verlieren, teilte der Konzern am Dienstag mit. So...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Why You Still Have to Dress for Success

Why You Still Have to Dress for Success


Even in this era of jeans and T-shirts in the office, I still get dressed up -- for work, for fun and even for a weekend night at home. My very first job in high school was at JCPenney, then out of college it was Nestle, and then out of graduate school it was Johnson & Johnson -- with a coat and tie the entire time.



from Biotech News
Share:

What You Can Achieve With Dividend Investing, A Johnson & Johnson Case Study

What You Can Achieve With Dividend Investing, A Johnson & Johnson Case Study


In this article, I explore why new dividend growth investors should focus on the long haul instead of short-term noise. Dividend growth investing is a long-term strategy but the poor performance of the market is creating doubt in the mind of new investors.



from Biotech News
Share:

Global Vaccine promises $5 million to develop Ebola vaccine

Global Vaccine promises $5 million to develop Ebola vaccine


The global vaccine alliance GAVI says it will donate $5 million toward developing the leading Ebola vaccine, hoping that it will be approved by a regulator by the end of 2017. If the vaccine is given the green light, GAVI says it will then create a stockpile to help stamp out future outbreaks of the lethal disease.



from Biotech News
Share:

Insider Buying: Neptune Technologies & Bioressources Inc (NTB)...

Insider Buying: Neptune Technologies & Bioressources Inc (NTB)...


Neptune Technologies & Bioressources Inc insider Mario Paradis acquired 10,000 shares of the firm's stock in a transaction that occurred on Monday, January 18th. The stock was bought at an average price of C$1.50 per share, with a total value of C$15,000.00.



from Biotech News
Share:

CDC: Ask pregnant women about trips to Zika outbreak areas

CDC: Ask pregnant women about trips to Zika outbreak areas


This 2006 file photo provided by the Centers for Disease Control and Prevention shows a female Aedes aegypti mosquito in the process of acquiring a blood meal from a human host. The The Centers for Disease Control and Prevention on Tuesday, Jan. 19, 2016, announced new guidance for doctors whose pregnant patients may have traveled to regions with a tropical illness linked to birth defects.



from Biotech News
Share:

Johnson & Johnson to cut about 3,000 jobs in medical devices

Johnson & Johnson to cut about 3,000 jobs in medical devices


Johnson & Johnson said Tuesday that it plans to cut about 3,000 jobs over the next two years as the health care conglomerate works to restructure its medical devices business. The New Brunswick, New Jersey, company said that amounts to more than 2 percent of its global workforce of around 127,000 people and 4 percent to 6 percent of its employee total in medical devices.



from Biotech News
Share:

FBI: Violent crime rose in first 6 months of 2015 over 2014

FBI: Violent crime rose in first 6 months of 2015 over 2014


Preliminary data released by the FBI show violent crime rose across the country in the first six months of 2015 compared to the same period the year before. Preliminary data released by the FBI show violent crime rose across the country in the first six months of 2015 compared to the same period the year before.



from Biotech News
Share:

Merck beruft neue Mitglieder der Geschäftsleitung

Merck beruft neue Mitglieder der Geschäftsleitung


image description
Der Gesellschafterrat der E. Merck KG hat zwei neue Mitglieder der Geschäftsleitung der Merck KGaA bestellt: Udit Batra (45), Leiter des Unternehmensbereichs Life Science, sowie Walter Galinat (59), Leiter des Unternehmensbereichs Performance Materials, werden zum 30. April 2016 unter Beibehaltung i...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

High court rejects appeal over $63M judgment in Motrin case

High court rejects appeal over $63M judgment in Motrin case


The Supreme Court has rejected an appeal from the manufacturer of Children's Motrin over a $63 million judgment awarded to a family whose daughter developed a life-threatening disease after taking the medicine. The justices on Tuesday let stand a lower court ruling that said Johnson & Johnson should pay the judgment awarded to the family of Samantha Reckis.



from Biotech News
Share:

MannKind: Out With The New And In With The Old Game-Plan For Success

MannKind: Out With The New And In With The Old Game-Plan For Success


I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions.



from Biotech News
Share:

Kenyan man charged for sharing photos of Somalia victims

Kenyan man charged for sharing photos of Somalia victims


A new government report estimates that this year's budget deficit will rise to $544 billion, an increase over prior estimates that can be attributed largely to tax cuts and spending increases passed by Congress... A new government report estimates that this year's budget deficit will rise to $544 billion, an increase over prior estimates that can be attributed largely to tax cuts and spending increases passed by Congress last... The Supreme Court is refusing to revive an Arkansas law that would have banned abortions after the 12th week of pregnancy if doctors can detect a fetal heartbeat.



from Biotech News
Share:

Carnage In Biotech: What's Hot And What's Not

Carnage In Biotech: What's Hot And What's Not


I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it .



from Biotech News
Share:

Family Time: Road to recovery: What you need to know about addiction

Family Time: Road to recovery: What you need to know about addiction


Drug and alcohol addiction can destroy careers, tear apart families and ruin lives. With 43,982 total drug-induced deaths each year, addiction continues to be a problem in the United States.



from Biotech News
Share:

Celsion Co. (CLSN) Raised to "Buy" at Zacks Investment Research

Celsion Co. (CLSN) Raised to "Buy" at Zacks Investment Research


The firm currently has a $1.50 price objective on the stock. Zacks Investment Research 's price objective would indicate a potential upside of 16.28% from the company's previous close.



from Biotech News
Share:

Effort to curb overuse of antibiotics amid cold, flu seasons

Effort to curb overuse of antibiotics amid cold, flu seasons


In this Oct. 8, 2013, file photo, a sign marks the entrance to the federal Centers for Disease Control and Prevention in Atlanta. Guidelines released Monday, Jan. 18, 2016, from CDC and the American College of Physicians, move beyond simple statements that antibiotics don't work for viruses like the common cold or the flu.



from Biotech News
Share:

MediciNova's Ibudilast And The Phase IIb Trial Offer Steady Outlook

MediciNova's Ibudilast And The Phase IIb Trial Offer Steady Outlook


I/we have no positions in any stocks mentioned, but may initiate a long position in MNOV over the next 72 hours. I wrote this article myself, and it expresses my own opinions.



from Biotech News
Share:

Studienabbrecher sind begehrt

Studienabbrecher sind begehrt


Jährlich brechen in Deutschland bis zu 100.000 Studierende ihr Studium ab. Für Arbeitgeber sind Studienabbrecher sehr attraktiv. Kammern und Bundesbildungsministerium bieten spezielle Programme an, um sie gezielt an Betriebe zu vermitteln. Test.de, das Onlineportal der Stiftung Warentest, erklärt, w...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Merck & Co vs. Merck KGaA: US-Konzern mit neuer Klage im Namensstreit

Merck & Co vs. Merck KGaA: US-Konzern mit neuer Klage im Namensstreit


(dpa) Neue Runde im langjährigen Namensstreit: Der US-Pharma- und Chemieriese Merck & Co hat den deutschen Konkurrenten Merck KGaA in den USA wegen missbräuchlicher Namensnutzung verklagt. Die Amerikaner wollen verhindern, dass der Darmstädter Konzern in den USA die Marke Merck vertritt und fordern ...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Zacks Investment Research Downgrades Bayer AG (BAYRY) to Hold

Zacks Investment Research Downgrades Bayer AG (BAYRY) to Hold


According to Zacks, "Bayer's revenues during the third quarter of 2015 were boosted by its newly launched pharmaceutical products. These products are expected to continue their strong run in the upcoming quarters as well.



from Biotech News
Share:

Jamaica advises women to delay pregnancy due to Zika virus

Jamaica advises women to delay pregnancy due to Zika virus


This 2006 photo provided by the Centers for Disease Control and Prevention shows a female Aedes aegypti mosquito in the process of acquiring a blood meal from a human host. On Friday, Jan. 15, 2016, U.S. health officials are telling pregnant women to avoid travel to Latin America and Caribbean countries with outbreaks of a tropical illness linked to birth defects.



from Biotech News
Share:

Biotech investor: 'None of us were as smart as we thought we were'

Biotech investor: 'None of us were as smart as we thought we were'


It wasn't that long ago that investors couldn't get enough of biotechnology stocks. Now it seems as if they can't get out of the sector fast enough.



from Biotech News
Share:

Shire PLC (SHP) Lifted to Outperform at BNP Paribas

Shire PLC (SHP) Lifted to Outperform at BNP Paribas


The brokerage currently has a GBX 5,700 target price on the biopharmaceutical company's stock. BNP Paribas' price objective points to a potential upside of 36.20% from the company's previous close.



from Biotech News
Share:

Landscape Shifting for M&A in 2016

Landscape Shifting for M&A in 2016


Low borrowing costs, market stability founded on a strengthening U.S. economy and a gaping tax loophole spurred a record year for mergers and acquisitions in 2015. Those same factors - in reverse - could derail a repeat performance in 2016.



from Biotech News
Share:

Johnson & Johnson (JNJ) Receives "AAA" Credit Rating

Johnson & Johnson (JNJ) Receives "AAA" Credit Rating


Johnson & Johnson has been given an "AAA" credit rating by analysts at Morningstar . The investment research firm's "AAA" rating indicates that the company is an extremely-low default risk.



from Biotech News
Share:

Zacks Investment Research Upgrades QLT Inc. (QLTI) to "Buy"

Zacks Investment Research Upgrades QLT Inc. (QLTI) to "Buy"


The firm presently has a $2.75 price objective on the stock. Zacks Investment Research 's target price suggests a potential upside of 13.64% from the stock's current price.



from Biotech News
Share:

Celgene Co. (CELG) Receives New Coverage from Analysts at Standpoint Research

Celgene Co. (CELG) Receives New Coverage from Analysts at Standpoint Research


The firm set a "buy" rating and a $130.00 price target on the biopharmaceutical company's stock. Standpoint Research's price target points to a potential upside of 26.14% from the stock's previous close.



from Biotech News
Share:

Hirntod nach Medikamententest in Frankreich

Hirntod nach Medikamententest in Frankreich


(dpa) Nach heftigen Nebenwirkungen bei einem Medikamententest in Frankreich liegt ein Versuchsteilnehmer hirntot im Krankenhaus. Vier weitere Probanden leiden unter neurologischen Beschwerden, die Ärzte fürchten bei einigen von ihnen bleibende Schäden. «Ihre Not hat mich erschüttert», sagte Gesundhe...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA


Novartis announced today that the US Food and Drug Administration has approved Cosentyx for two new indications - the treatment of adult patients with active ankylosing spondylitis and active psoriatic arthritis . AS and PsA are both life-long, painful and debilitating inflammatory diseases that affect the joints and/or spine.



from Biotech News
Share:

Novo Nordisk A/S (NVO) Receives Sell Rating from Zacks Investment Research

Novo Nordisk A/S (NVO) Receives Sell Rating from Zacks Investment Research


's stock had its "sell" rating reissued by Zacks Investment Research in a research report issued to clients and investors on Sunday, MarketBeat.Com reports. According to Zacks, "Novo Nordisk's third-quarter 2015 results were strong with revenues increased on the back of robust performance from Victoza and Levemir as well as significant contributions from Tresiba and Saxenda.



from Biotech News
Share:

Pfizer Inc. (PFE) Sees Large Increase in Short Interest

Pfizer Inc. (PFE) Sees Large Increase in Short Interest


Pfizer Inc. saw a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 123,454,015 shares, a growth of 44.1% from the December 15th total of 85,657,779 shares, MarketBeat Ratings reports.



from Biotech News
Share:

Baby born in Hawaii with brain damage confirmed to have Zika infection

Baby born in Hawaii with brain damage confirmed to have Zika infection


REUTERS: A baby born with brain damage at a hospital in Oahu, Hawaii, was infected by the Zika virus, U.S. health officials confirmed on Saturday, apparently the first case of the mosquito-borne virus in a birth on U.S. soil. The mother became ill with the Zika virus while living in Brazil in May 2015 and the baby was likely infected in the womb, Hawaiian state health officials and the U.S. Centers for Disease Control and Prevention said.



from Biotech News
Share:

Haiti: Six years after quake, UN cites progress but warns of 'deteriorating' situation

Haiti: Six years after quake, UN cites progress but warns of 'deteriorating' situation


New York, Jan 16 :Six years after the devastating earthquake that killed more than 200,000 people and left at least 1.5 million homeless, the United Nations is underlining that humanitarian action has achieved significant results, but that the situation has been deteriorating since June. Despite the progress achieved to date, there are still nearly 60,000 people living in IDP [internally displaced persons] camps in vulnerable situations and in need of humanitarian assistance and durable solutions, said Enzo di Taranto, Head of the United Nations Office for the Coordination of Humanitarian Affairs in Haiti.



from Biotech News
Share:

MannKind Co. (MNKD) Upgraded to "Buy" at Zacks Investment Research

MannKind Co. (MNKD) Upgraded to "Buy" at Zacks Investment Research


The brokerage presently has a $1.00 target price on the biopharmaceutical company's stock. Zacks Investment Research 's price objective indicates a potential upside of 7.71% from the company's current price.



from Biotech News
Share:

What Pharma/Biotech Investors Need To Know About Adaptive Trials

What Pharma/Biotech Investors Need To Know About Adaptive Trials


The FDA allows for adaptive drug trials during which key protocols may be altered during the course of the trial depending on interim results. Investors concerned with pharmaceutical or biotech drug development, from early to late stages, need to be aware of the benefits and risks of adaptive trials because their use and interpretation can impact corporate valuations.



from Biotech News
Share:

Sinovac Biotech Ltd. (SVA) Sees Significant Increase in Short Interest

Sinovac Biotech Ltd. (SVA) Sees Significant Increase in Short Interest


Sinovac Biotech Ltd. was the target of a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 1,297,916 shares, a growth of 34.1% from the December 15th total of 967,984 shares, Market Beat.com reports.



from Biotech News
Share:

Major drugmakers push back in US price debate

Major drugmakers push back in US price debate


With a backlash brewing over the price of medicines in the United States, drugmakers are pushing back with a new message: Most people don't pay retail. Pharmaceutical tablets and capsules in foil strips are arranged on a table in this picture illustration taken in Ljubljana September 18, 2013.



from Biotech News
Share:

Pregnant women told to avoid countries with Zika outbreaks

Pregnant women told to avoid countries with Zika outbreaks


This 2006 photo provided by the Centers for Disease Control and Prevention shows a female Aedes aegypti mosquito in the process of acquiring a blood meal from a human host. On Friday, Jan. 15, 2016, U.S. health officials are telling pregnant women to avoid travel to Latin America and Caribbean countries with outbreaks of a tropical illness linked to birth defects.



from Biotech News
Share:

Shark Tank funds fewer women than men, with less money

Shark Tank funds fewer women than men, with less money


When Ann Crady Weiss pitched her first start up - a social network known as Maya's Mom that would allow mothers to seek advice and share their experiences - male investors weren't exactly enamored with the idea. "There were many investors I spoke to who said moms don't have time for social networks," Weiss told Mashable.



from Biotech News
Share:

Pregnant women told to avoid countries with Zika outbreaks

Pregnant women told to avoid countries with Zika outbreaks


This 2006 photo provided by the Centers for Disease Control and Prevention shows a female Aedes aegypti mosquito in the process of acquiring a blood meal from a human host. On Friday, Jan. 15, 2016, U.S. health officials are telling pregnant women to avoid travel to Latin America and Caribbean countries with outbreaks of a tropical illness linked to birth defects.



from Biotech News
Share:

These 6 Things Need To Happen Before Gilead Shares Go Higher

These 6 Things Need To Happen Before Gilead Shares Go Higher


I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it .



from Biotech News
Share:

Merck pays $830 M to settle class-action case over Vioxx

Merck pays $830 M to settle class-action case over Vioxx


Merck will pay $830 million to resolve a federal class-action lawsuit involving shareholders and the painkiller Vioxx, which the drugmaker pulled from the market years ago over safety concerns. Merck said Friday that the case involved people who purchased its securities between 1999 and 2004.



from Biotech News
Share:

10 biotech stocks to buy at 'silly' cheap prices

10 biotech stocks to buy at 'silly' cheap prices


If you watched biotechnology stocks rally for the past few years without enjoying the ride, now's the time to make up for lost ground. The sector has been hammered, down to valuations not seen in years, but for reasons that don't add up.



from Biotech News
Share:

Raymond James Trust Buys $13,314,000 in Merck & Co., Inc. (MRK) Shares

Raymond James Trust Buys $13,314,000 in Merck & Co., Inc. (MRK) Shares


Raymond James Trust boosted its stake in shares of Merck & Co., Inc. by 12.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 252,067 shares of the company's stock after buying an additional 28,307 shares during the period.



from Biotech News
Share:

ASHP Disappointed in MedPAC Recommendation to Congress on 340B

ASHP Disappointed in MedPAC Recommendation to Congress on 340B


ASHP announced today that it is extremely disappointed in the recommendation to Congress by the Medicare Payment Advisory Commission (MedPAC) to cut Medicare payments to safety net hospitals by 10 percent for drugs purchased under the 340B drug discount program.   “ASHP is disappointed that MedPAC did not assess the negative impact this recommendation could have on the sickest and most vulnerable patients that are served by our nation’s safety net hospitals,” said Kasey K. Thompson, Pharm.D., M.S., M.B.A., ASHP vice president of policy, planning and communications.   Although the recommendation is nonbinding, ASHP is concerned that the proposed reduction in Medicare payments will negatively impact hospitals’ ability to provide care to uninsured and underinsured patients. MedPAC voted in favor of the recommendation to Congress as a cost-saving measure for the Medicare program. MedPAC is a nonpartisan legislative branch agency that provides Congress with analysis and policy advice on the Medicare program.

ASHP Health-System Pharmacy Press Releases and Announcements

Öffnungszeiten der Schufa

Share:

Johnson & Johnson (JNJ) Position Decreased by RNC Capital Management

Johnson & Johnson (JNJ) Position Decreased by RNC Capital Management


RNC Capital Management lowered its stake in shares of Johnson & Johnson by 14.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 337,341 shares of the company's stock after selling 55,974 shares during the period.



from Biotech News
Share:

Report: Cruise ship stomach sickness becoming less common

Report: Cruise ship stomach sickness becoming less common


This Friday, Feb. 26, 2010 file photo shows the cruise ship Celebrity Mercury docked at the South Carolina State Ports Authority passenger terminal in downtown Charleston S.C., after passengers became sick with a stomach bug. According to figures released on Thursday, Jan. 14, 2016 by the Centers for Disease Control and Prevention, cruise ship passengers are getting sick with a stomach bug less often.



from Biotech News
Share:

Why Confirmation Bias Is A Portfolio Killer

Why Confirmation Bias Is A Portfolio Killer


I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions.



from Biotech News
Share:

Zacks: Analysts Set $6.00 Price Target for Sinovac Biotech Ltd.

Zacks: Analysts Set $6.00 Price Target for Sinovac Biotech Ltd.


Sinovac Biotech Ltd. has earned an average broker rating score of 3.00 from the one analysts that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold recommendation.



from Biotech News
Share:

Alstom S.A. (ALO) Given a a 31.00 Price Target at S&P Equity Research

Alstom S.A. (ALO) Given a a 31.00 Price Target at S&P Equity Research


The firm currently has a a "buy" rating on the stock. Other research analysts also recently issued research reports about the stock.



from Biotech News
Share:

a Stay of Litigation Pending Ipr Does Not Provide a Basis For Extending 30-Stay of Fda Anda Approval

a Stay of Litigation Pending Ipr Does Not Provide a Basis For Extending 30-Stay of Fda Anda Approval


On December 11, 2015, the United States District Court for the Southern District of Indiana granted a motion to stay a Hatch-Waxman litigation pending the outcome of inter partes reviews on two of the patents-in-suit in the litigation. See Eli Lilly and Company, et al. vs. Accord Healthcare Inc., et al. , No.



from Biotech News
Share:

At Biotech Party, Gender Diversity Means Cocktail Waitresses

At Biotech Party, Gender Diversity Means Cocktail Waitresses


Outside the Exploratorium, an airy event space on San Francisco's waterfront, a long line of mostly male biotechnology investors and executives waited to get into a party. And, yes, there they were, in matching short, tight, black dresses with shoulder cutouts.



from Biotech News
Share:

CDC: Strong signs Brazil birth defects are tied to mosquito

CDC: Strong signs Brazil birth defects are tied to mosquito


In this Dec. 23, 2015, file photo, 10-year-old Elison nurses his 2-month-old brother Jose Wesley, who was born with microcephaly, at their house in Poco Fundo, Pernambuco state, Brazil. The U.S. Centers for Disease Control and Prevention said Wednesday, Jan. 13, 2016, that it has found the strongest evidence so far of a possible link between a mosquito-borne virus and a surge of birth defects in Brazil.



from Biotech News
Share:

Unlocking Deep Value With Arrowhead Research

Unlocking Deep Value With Arrowhead Research


I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it .



from Biotech News
Share:

Teens regularly exposed to secondhand smoke

Teens regularly exposed to secondhand smoke


Close to half of U.S. middle and high school students who never used tobacco themselves were exposed to secondhand smoke in 2013, often at home or in cars, according to a new study from the Centers for Disease Control and Prevention in Atlanta. Progress has been made in creating smoke-free public places and reducing secondhand smoke exposure among our nation's youth, but many remain exposed, said lead author Israel Agaku.



from Biotech News
Share:

Childrena s cough syrup recall: What parents should know

Childrena s cough syrup recall: What parents should know


Two kinds of children's cough syrup are being recalled after dosing cups with incorrect markings were included in the packaging, prompting concerns that kids could become sick after an accidental overdose. The Perrigo Company is voluntarily recalling two batches of its children's guaifenesin grape liquid and three batches of its children's guaifenesin DM cherry liquid after a dosing cup with the wrong markings was included with the 4 oz.



from Biotech News
Share:

Drug Firms Team Up on Cancer Trials

Drug Firms Team Up on Cancer Trials


A handful of pharmaceutical companies, including biotech giant Amgen, are joining together to test cocktails of their latest cancer drugs in an ambitious initiative aimed at rapidly developing new treatments -- but one that's gotten off to a shaky start. Cancer MoonShot 2020 was announced Monday by Dr. Patrick Soon-Shiong, a billionaire Los Angeles oncologist who is spearheading the program, at a healthcare investor conference in San Francisco.



from Biotech News
Share:

Drugmakers ring in 2016 with hefty price hikes

Drugmakers ring in 2016 with hefty price hikes


If you need one of a number of drugs treating ailments ranging from heart arrhythmia to severe pain, you may be feeling another type of discomfort this year: a hit to the wallet. Drugmakers including Pfizer and Allergan have boosted prices on many brand-name medications since last month.



from Biotech News
Share:

Most actively traded companies on the TSX

Most actively traded companies on the TSX


Rubicon Minerals Corp. . Miner. Down two cents, or 40 per cent, to three cents on 12.2 million shares.



from Biotech News
Share:

Children's Cough Medicine Recalled Due to Potential Overdose

Children's Cough Medicine Recalled Due to Potential Overdose


A company that sells over-the-counter children's cough medicine is voluntarily recalling two batches of its product due to a problem with mismarked dosing cups. Perrigo Company announced that following the recent recall of certain dosing cups by its supplier, it has initiated a voluntary product recall for two batches of children's guaifenesin grape liquid children's guaifenesin DM cherry liquid .



from Biotech News
Share:

Company recalls children's cough medicine

Company recalls children's cough medicine


A company that sells children's cough medicine at Kroger, CVS, Dollar General and Rite-Aid stores is recalling the product due to overdosing concerns. The Perrigo Company announced this week that it initiated a voluntary nationwide recall for two batches of its children's guaifenesin grape liquid and three batches of its children's guaifenesin DM cherry liquid.



from Biotech News
Share:

Alzheimer: Evotec erreicht wichtigen Meilenstein

Alzheimer: Evotec erreicht wichtigen Meilenstein


Evotec AG gab das Erreichen eines wichtigen Meilensteins in der TargetAD-Kooperation mit Janssen Pharmaceuticals, Inc. für die Überführung eines Projekts in den weiteren Wirkstoffforschungsprozess bekannt. Dieser Meilenstein wurde im Jahr 2015 erreicht und seine Umsatzerlöse werden im Geschäftsjahr ...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Milliardendeal in der Pharmabranche

Milliardendeal in der Pharmabranche


(dpa-AFX) Die Übernahmewelle in der Pharmaindustrie bricht nicht ab: Der britisch-irische Konzern Shire will den US-Konkurrenten Baxalta für rund 32 Milliarden US-Dollar übernehmen. Das Management beider Unternehmen habe einem Zusammenschluss zugestimmt, teilten Shire und Baxalta am Montag mit. Die ...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

A (Potentially) Final Look At MannKind

A (Potentially) Final Look At MannKind


As everybody reading this article undoubtedly knows by now, Sanofi gave notice last Monday that it was terminating its licensing agreement with MannKind , relinquishing all rights to market Afrezza. Although the speculation about this possibility started circulating very soon after the inhaled insulin was launched, fanned by the small biotech's various vocal detractors, many true believers in the drug, certainly including myself, were stunned by the news, with the stock losing almost half of its already depressed value.



from Biotech News
Share:

Pfizer, Allergan CEOs: Tie-up aims to produce more meds, sales, isn't focused on cutting costs

Pfizer, Allergan CEOs: Tie-up aims to produce more meds, sales, isn't focused on cutting costs


The heads of drugmakers Pfizer and Allergan said Tuesday that the record $160 billion combination they're planning is meant to produce more medicines and boost revenue, not to just slash jobs and other costs as the companies previously have done. The deal announced last November would move Pfizer's official headquarters for tax purposes from New York to Allergan's base in Ireland.



from Biotech News
Share:

No, Virginia; Biotech Is Not In A Bubble

No, Virginia; Biotech Is Not In A Bubble


I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it .



from Biotech News
Share:

Market Extra: As biotech stocks knife under their 'Hillary' low, analysts still say buy 'em

Market Extra: As biotech stocks knife under their 'Hillary' low, analysts still say buy 'em


Biotech stocks have dived to levels last seen in late 2014, in another sign of how the new year has hammered riskier plays. It is "tough in biotech right now," RBC analysts said in a note dated Tuesday.



from Biotech News
Share:

U.S. copy of GSK's Advair a step closer as Mylan files generic version

U.S. copy of GSK's Advair a step closer as Mylan files generic version


Jan 12 The arrival of cheap generic versions of GlaxoSmithKline's top-selling lung drug Advair has moved a step closer with confirmation from Mylan that it has submitted a generic version for approval. Mylan said late on Monday it had filed an abbreviated new drug application to the U.S. Food and Drug Administration in December.



from Biotech News
Share:

Johnson & Johnson: Is This What You Were Waiting For?

Johnson & Johnson: Is This What You Were Waiting For?


With the "minute" drop in the stock market and all the sensationalized media forecast, I think now is the appropriate time to answer the question: "Is now the right time to buy?" Johnson & Johnson's The yield is currently at 3.01%. This is the starting point where investors start to lose focus and begin to convolute and complicate the matter.



from Biotech News
Share:

Twombly's Teeth

Twombly's Teeth


Occasionally a would-be plaintiff asks whether one can file an antitrust claim and then get some discovery to back it up. In Eastman v.



from Biotech News
Share:

Wall Street Closes Mostly Higher as Oil Drops A...

Wall Street Closes Mostly Higher as Oil Drops A...


The Nasdaq dropped 5.64 to end the session at 4637.99, while the S&P 500 closed at 1923.67 up 1.64 from its open. Investors continue to fret over the world's second-largest economy.



from Biotech News
Share:

Children's cold syrup recall expands

Children's cold syrup recall expands


Nine over-the-counter drug retailers, including CVS, Stop & Shop and Giant, are recalling two flavors of children's liquid cold medicine products from their shelves because of a potential overdose risk. The products are sold by distributors nationwide under a variety of brand names.



from Biotech News
Share:

Emergent Biosolutions Announces Preliminary 2015 Financial Results,...

Emergent Biosolutions Announces Preliminary 2015 Financial Results,...


Emergent Biosolutions Announces Preliminary 2015 Financial Results, Provides 2016 Financial Outlook, and Outlines New Five-Year Strategic Growth Plan Six products in clinical or advanced development, with at least three being dual use, prioritizing those with third party funding GAITHERSBURG, Md., Jan. 11, 2016 -- Emergent BioSolutions Inc. today announced preliminary unaudited 2015 financial results and provided guidance for 2016. The company also provided an overview of the key financial and operational goals to be achieved by year end 2020 through its next five-year strategic growth plan.



from Biotech News
Share:

High court won't hear appeal over $124M drug penalty

High court won't hear appeal over $124M drug penalty


The Supreme Court won't hear an appeal from a Johnson & Johnson subsidiary assessed more than $124 million in penalties for deceptive marketing of an anti-psychotic drug. The justices on Monday let stand a lower court ruling that said Janssen Pharmaceuticals, Inc. should pay the penalties for violations of South Carolina law.



from Biotech News
Share:

Trial of Freddie Gray van driver delayed by appeals court

Trial of Freddie Gray van driver delayed by appeals court


The Supreme Court won't hear an appeal from a Johnson & Johnson subsidiary assessed more than $124 million in penalties for deceptive marketing of an anti-psychotic drug. The Supreme Court won't hear an appeal from a Johnson & Johnson subsidiary assessed more than $124 million in penalties for deceptive marketing of an anti-psychotic drug.



from Biotech News
Share:

Shire to Combine with Baxalta in Deal Valued at About $32 Billion

Shire to Combine with Baxalta in Deal Valued at About $32 Billion


Shire Plc agreed to buy Baxalta Inc. for about $32 billion to become the world's biggest maker of so-called orphan drugs for rare diseases. The price includes 0.1482 of Shire's American depositary receipts and $18 in cash for each Baxalta share held, the Dublin-based drugmaker said in a statement.



from Biotech News
Share:

West Virginia Sues Prescription Drug Wholesaler For 'Flooding' State

West Virginia Sues Prescription Drug Wholesaler For 'Flooding' State


West Virginia's attorney general has accused one of the nation's largest pharmaceutical drug wholesalers of flooding the state with tens of millions of prescription pills in violation of state law. Attorney General Patrick Morrisey on Friday announced a lawsuit against San Francisco-based McKesson Corp. Among other things, the lawsuit alleges violations of state consumer protection laws and the Uniform Controlled Substances Act.



from Biotech News
Share:

Alexion Pharmaceuticals, Inc. (ALXN) Position Decreased by EQIS Capital Management

Alexion Pharmaceuticals, Inc. (ALXN) Position Decreased by EQIS Capital Management


EQIS Capital Management decreased its stake in Alexion Pharmaceuticals, Inc. by 51.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 9,974 shares of the biopharmaceutical company's stock after selling 10,740 shares during the period.



from Biotech News
Share:

Illumina, partners make $100 million bet to detect cancer via blood test

Illumina, partners make $100 million bet to detect cancer via blood test


Gene sequencing company Illumina Inc is going after the next big advance in cancer detection, working to develop a universal blood test to identify early-stage cancers in people with no symptoms of the disease. On Sunday, San Diego-based Illumina said it would form a new company, called Grail, with more than $100 million in Series A financing.



from Biotech News
Share:

Transaktionen "historischen Ausmaßes" im Chemie- & Pharma-Bereich in 2016 erwartet

Transaktionen "historischen Ausmaßes" im Chemie- & Pharma-Bereich in 2016 erwartet


Weltweit konnte die Chemie- und Pharmabranche im abgelaufenen Jahr Fusionen und Übernahmen im Wert von 372 Milliarden US-Dollar verzeichnen. Das bedeutet im Vergleich zu 2014 (214 Mrd. US-Dollar) eine Zunahme um 74 Prozent. Wesentliche Ursache für den starken Anstieg waren einige sehr große Deals im...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Fired Novo Nordisk rep claims retaliation in miscarriage discrimination suit

Fired Novo Nordisk rep claims retaliation in miscarriage discrimination suit


PLAINSBORO - A former sales rep for Novo Nordisk claims in a whistleblower suit that the Danish pharmaceutical giant discriminated against her for getting pregnant, then callously fired her after she had a miscarriage. Alicia Clark-Unusan's lawsuit against the company with U.S. headquarters in Plainsboro portrays a highly competitive and cutthroat company culture, with claims that in her case, it was more dedicated to its sales numbers than its employees' well being - or to the state's laws against discrimination and retaliation.



from Biotech News
Share:

E-cigarette ads reach 7 in 10 young adults, CDC says

E-cigarette ads reach 7 in 10 young adults, CDC says


The Centers for Disease Control and Prevention issued a report Tuesday that stated about 70 percent of teens are exposed to e-cigarette ads through numerous mediums. A federal report released Tuesday indicated 7 in 10 teens are exposed to e-cigarette advertising in retail stores, the Internet and on TV.



from Biotech News
Share:

Merck & Co., Inc. (MRK) Shares Sold by Kempner Capital Management

Merck & Co., Inc. (MRK) Shares Sold by Kempner Capital Management


Kempner Capital Management decreased its position in Merck & Co., Inc. by 4.6% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 44,768 shares of the company's stock after selling 2,164 shares during the period.



from Biotech News
Share:

Barclays Increases Hologic, Inc. (HOLX) Price Target to $42.00

Barclays Increases Hologic, Inc. (HOLX) Price Target to $42.00


The firm currently has an "equal weight" rating on the stock. Barclays' price objective indicates a potential upside of 14.91% from the stock's previous close.



from Biotech News
Share:

Fragasso Group Has $2,482,000 Stake in Johnson & Johnson

Fragasso Group Has $2,482,000 Stake in Johnson & Johnson


Fragasso Group decreased its position in Johnson & Johnson by 0.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 24,167 shares of the company's stock after selling 94 shares during the period.



from Biotech News
Share:

Mead Johnson Nutrition CO (MJN) Cut to Sell at Zacks Investment Research

Mead Johnson Nutrition CO (MJN) Cut to Sell at Zacks Investment Research


According to Zacks, "Mead Johnson posted dismal financial numbers in the third quarter of 2015, missing the Zacks Consensus Estimate of both earnings and revenues.The company's segmental performance was also considerably weak. Moreover, the near-term challenges in its emerging market segments are expected to continue in 2016 as well.



from Biotech News
Share:

GlaxoSmithKline plc's (GSK) Neutral Rating Reaffirmed at BNP Paribas

GlaxoSmithKline plc's (GSK) Neutral Rating Reaffirmed at BNP Paribas


's stock had its "neutral" rating restated by analysts at BNP Paribas in a report issued on Friday, MarketBeat Ratings reports. They presently have a GBX 1,400 target price on the stock.



from Biotech News
Share:

Astorino announces $1.2 bilion private sector investment in biotech complex

Astorino announces $1.2 bilion private sector investment in biotech complex


In a far-reaching initiative to strengthen Westchester County as a major innovation hub, County Executive Robert P. Astorino announced a $1.2 billion private investment today to build a bioscience and technology complex on a vacant site owned by the county in Valhalla adjacent to the Westchester Medical Center and New York Medical College. Called the Westchester BioScience & Technology Center, the nearly 3 million-square-foot, mixed-use complex on 80 acres would be developed by Fareri Associates, a premier developer in Westchester and Fairfield counties with more than 40 years of experience.



from Biotech News
Share:

Belviq Sales Close Out 2015 With A Slump

Belviq Sales Close Out 2015 With A Slump


When 2015 started Belviq from Arena Pharmaceuticals was leading the pack in scripts sold in the branded anti-obesity pill space. When 2015 finished Belviq was in last place and sales actually saw a dip in sales on a year over year basis.



from Biotech News
Share:

Pfizer Hikes Prices for Over 100 Drugs on January 1

Pfizer Hikes Prices for Over 100 Drugs on January 1


Pfizer Inc, which plans a $160-billion merger with Ireland-based Allergan Plc to slash its U.S. tax bill, on Jan. 1 raised U.S. prices for more than 100 of its drugs, some by as much as 20 percent, according to statistics compiled by global information services company Wolters Kluwer. Pfizer confirmed a 9.4 percent increase for heavily advertised pain drug Lyrica, which generated $2.3 billion in 2014 U.S. sales; a 12.9 percent increase for erectile dysfunction drug Viagra, which had 2014 U.S. sales of $1.1 billion; and a 5 percent increase for Ibrance, a novel breast cancer drug launched last year at a list price of $9,850 per month, or $118,200 per year.



from Biotech News
Share:

Biodel: A Beaten Down Biotech Trading At A Large Discount

Biodel: A Beaten Down Biotech Trading At A Large Discount


Biodel is a beaten down biotech stock that is currently trading at a large discount to net cash. The company is pursuing strategic alternatives that I believe will result in a reverse merger.



from Biotech News
Share:

West Virginia attorney general sues drug wholesaler

West Virginia attorney general sues drug wholesaler


West Virginia's attorney general has accused one of the nation's largest pharmaceutical drug wholesalers of flooding the state with tens of millions of prescription pills in violation of state law.



from Biotech News
Share:

Biotech Bargains Abound

Biotech Bargains Abound


I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it .



from Biotech News
Share:

Healios and Athersys Enter Into Regenerative Medicine Partnership for ...

Healios and Athersys Enter Into Regenerative Medicine Partnership for ...


Healios K.K. and Athersys, Inc. have announced a partnership and license agreement that will focus on the development and commercialization of novel cell therapy treatments, including MultiStemA for the treatment of ischemic stroke and potentially other indications, in Japan. The partnership involves MultiStem, a proprietary, patented off-the-shelf stem cell therapy being developed by Athersys, with an initial focus on treating ischemic stroke.



from Biotech News
Share:

Joseph Podolski Purchases 11,677 Shares of Repros Therapeutics Inc (RPRX) Stock

Joseph Podolski Purchases 11,677 Shares of Repros Therapeutics Inc (RPRX) Stock


Repros Therapeutics Inc CEO Joseph Podolski purchased 11,677 shares of the firm's stock in a transaction that occurred on Thursday, January 7th. The shares were bought at an average price of $1.18 per share, for a total transaction of $13,778.86.



from Biotech News
Share:

Zoo staff infected by TB after exposure to elephants

Zoo staff infected by TB after exposure to elephants


A report from the Centers for Disease Control and Prevention says seven staff members at the Oregon Zoo tested positive for tuberculosis after an outbreak among three elephants started in 2013. The seven had a latent form of the respiratory disease and displayed no symptoms.



from Biotech News
Share:

Huimin Wang Sells 13,650 Shares of Edwards Lifesciences Corp (EW) Stock

Huimin Wang Sells 13,650 Shares of Edwards Lifesciences Corp (EW) Stock


Edwards Lifesciences Corp VP Huimin Wang sold 13,650 shares of the stock in a transaction that occurred on Tuesday, January 5th. The shares were sold at an average price of $78.50, for a total transaction of $1,071,525.00.



from Biotech News
Share:

Claims Are Construed In Nameda Dispute

Claims Are Construed In Nameda Dispute


Forest Laboratories, Inc., et al. v. Teva Pharmaceuticals USA, Inc., et al., C.A. Nos.



from Biotech News
Share:

2016 Biotech Stock Prediction: It's Going to Be a Bummer Year, Folks

2016 Biotech Stock Prediction: It's Going to Be a Bummer Year, Folks


I'm only making one big prediction this year: The five-year party which saw biotech stocks outperform the broader markets comes to an end in 2016. Good biotech science marches on but negative fund flows, a continued flurry of negative headlines about drug prices and the presidential election all contribute to lousy stock performance overall.



from Biotech News
Share:

Evotec und UCB gehen mehrjährige Vereinbarung im Bereich Substanzverwaltung ein

Evotec und UCB gehen mehrjährige Vereinbarung im Bereich Substanzverwaltung ein


Evotec AG gab eine EVT Execute-Zusammenarbeit mit UCB bekannt, die eine umfassende Lösung für UCBs globale Substanzverwaltungsanforderungen bietet. Im Rahmen der Vereinbarung wird Evotec UCBs Substanzbibliothek von ihrer modernen Substanzverwaltungseinrichtung in Toulouse, Frankreich, verwalten. Die...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

CDC: This Is America's Most Sleep-Deprived Group

CDC: This Is America's Most Sleep-Deprived Group


Sleep problems are widespread in the US, affecting adults and kids alike, but a new survey by the Centers for Disease Control and Prevention finds that single moms not only sleep less than any other demographic, they also have a harder time falling and staying asleep and they are more likely to wake up not feeling rested most mornings, reports the Los Angeles Times . { "position1" : { "type" : "track", "id" : 5917180, "name" : "Relaxing Rain Sounds", "description" : "Nature Sounds - A Day Of Rain", "artist" : "Technomind", "artistid" : "173485" } } "These results are not surprising," one sleep scientist not involved in the research tells Live Science .



from Biotech News
Share:

Agenus Inc (AGEN) Given Buy Rating at HC Wainwright

Agenus Inc (AGEN) Given Buy Rating at HC Wainwright


's stock had its "buy" rating reiterated by investment analysts at HC Wainwright in a research note issued on Thursday, MarketBeat.Com reports. They presently have a $10.00 price target on the stock.



from Biotech News
Share:

EQIS Capital Management Boosts Stake in Sinovac Biotech Ltd.

EQIS Capital Management Boosts Stake in Sinovac Biotech Ltd.


EQIS Capital Management boosted its position in Sinovac Biotech Ltd. by 6,472.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission . The firm owned 240,674 shares of the biopharmaceutical company's stock after buying an additional 237,012 shares during the period.



from Biotech News
Share:

Jefferies' Best Biotech Ideas For 2016

Jefferies' Best Biotech Ideas For 2016


In a report issued Wednesday, Jefferies' Biotechnology Equity Research Team shared its outlook, key themes and best ideas in the biotechnology industry for 2016 and beyond. After a volatile 2015, the experts assured they would be selective into the new year as sector headwinds persist.



from Biotech News
Share:

DoctoRx Positions For 2016: My No. 1 Risk Factor Is The Flood Of Money Into Biotech

DoctoRx Positions For 2016: My No. 1 Risk Factor Is The Flood Of Money Into Biotech


DoctoRx writes about a broad array of investment opportunities, but as a former internist and cardiology specialist, he brings particular insight to the biotech and healthcare arena. Per his Seeking Alpha bio, he has C-level experience and has been a pharmaceutical inventor and entrepreneur.



from Biotech News
Share:

The MannKind Story Has Ended

The MannKind Story Has Ended


I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions.



from Biotech News
Share:

Pharmakonzern Eli Lilly legt Latte nur vorsichtig höher

Pharmakonzern Eli Lilly legt Latte nur vorsichtig höher


(dpa-AFX) Der US-Pharmakonzern Eli Lilly legt die Latte nach fünf Jahren des Abschwungs nur vorsichtig wieder höher. Für 2016 peilt der Vorstand einen Umsatz von 20,2 bis 20,7 Milliarden US-Dollar an, wie das Unternehmen am Dienstag in Indianapolis mitteilte. Das ist zwar mehr als die für 2015 ausge...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Biotech stocks to get the heart racing...or slowing

Biotech stocks to get the heart racing...or slowing


So begins the year of the stock picker, as investors fret over a local market that they expect will struggle to provide decent returns. Notoriously volatile and tricky to pick, biotechnology stocks gave nimble investors plenty of opportunity to outperform bluechip stalwarts like miners and banks in 2015 and are set to provide some wild rides in 2016 too.



from Biotech News
Share:

Valeant names Howard Schiller as interim CEO

Valeant names Howard Schiller as interim CEO


Valeant Pharmaceuticals has named former finance chief Howard Schiller as interim CEO while the troubled drug company's chairman and chief executive remains hospitalized with severe pneumonia. Valeant said Tuesday that J. Michael Pearson is still on medical leave, and it did not know when he would return.



from Biotech News
Share:

Has Valeant Put Pearson In Its Rear View?

Has Valeant Put Pearson In Its Rear View?


According to Reuters , Valeant is looking to appoint an interim chief to replace CEO Mike Pearson who remains hospitalized with a severe case of pneumonia: Valeant Pharmaceuticals International Inc is looking to appoint an interim chief executive officer to replace Michael Pearson as he recovers from a severe case of pneumonia, a source familiar with the matter told Reuters. The source did not clarify whether the CEO would be temporary or would replace Pearson permanently.



from Biotech News
Share:

Health agency takes on advertising for electronic cigarettes

Health agency takes on advertising for electronic cigarettes


" The nation's lead public health agency on Tuesday focused its attack on electronic cigarettes on the issue of advertising, saying too many kids see the ads. There are bans on TV commercials and some other types of marketing for regular cigarettes but there are no restrictions on advertisements for e-cigarettes.



from Biotech News
Share:

CEO Frazier: Merck is eager for deals, sees strong prospects for drugs for cancer, hepatitis C

CEO Frazier: Merck is eager for deals, sees strong prospects for drugs for cancer, hepatitis C


Merck's chief executive says the drugmaker is "raring to go" on deals this year, particularly for small and midsize acquisitions of companies or their experimental drugs. CEO Kenneth Frazier, speaking Tuesday at a Goldman Sachs conference of CEOs of health care companies in Boston, also said he expects more approvals and growing sales from new cancer drug Keytruda.



from Biotech News
Share:

A rare stumble for biotech pioneer Alfred Mann

A rare stumble for biotech pioneer Alfred Mann


Alfred Mann, who has founded 17 companies, built a fortune that at one point topped $2 billion. Over seven decades, billionaire Alfred Mann has founded 17 companies, including ones that help the blind see and the deaf hear.



from Biotech News
Share:

Actelion Sees Uptravi Price Of $160,000-170,000/Patient

Actelion Sees Uptravi Price Of $160,000-170,000/Patient


Swiss drug company Actelion expects an average annual per-patient price for its new pulmonary arterial hypertension medicine in the United States of $160,000 to $170,000, before rebates, Chief Operating Officer Otto Schwarz told analysts on Tuesday. The drug, Uptravi, won approval from the U.S. Food and Drug Administration last month and went on sale this week, giving doctors another option to treat the deadly disease that kills victims within a few years.



from Biotech News
Share:

Esperion Therapeutics: Too Much Uncertainty To Go Long

Esperion Therapeutics: Too Much Uncertainty To Go Long


I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions.



from Biotech News
Share:

US indexes slip; GM, Ford fall after missing sales forecasts

US indexes slip; GM, Ford fall after missing sales forecasts


Specialist Ronnie Howard, center, works on the floor of the New York Stock Exchange, Tuesday, Jan. 5, 2016. U.S. stocks are opening modestly higher as trading stabilizes a day after a plunge in China unsettled investors around the globe.



from Biotech News
Share:

US stocks slip; GM and Ford fall after sales reports

US stocks slip; GM and Ford fall after sales reports


U.S. stocks are inching mostly lower Tuesday as global markets stabilize a day after a plunge in China unsettled investors worldwide. Health care stocks were the biggest gainers as drugmakers moved modestly higher.



from Biotech News
Share:

Premarket Biotech Digest: Exelixis Rallies, Shire-Baxalta Deal, Lipocine Commences Mid-Stage Study

Premarket Biotech Digest: Exelixis Rallies, Shire-Baxalta Deal, Lipocine Commences Mid-Stage Study


I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it .



from Biotech News
Share:

Drugmaker Lilly's 2016 forecast misses Street expectations

Drugmaker Lilly's 2016 forecast misses Street expectations


The drugmaker says it expects adjusted earnings in the new year to range between $3.45 and $3.55 per share, excluding charges like deal integration costs. It predicts revenue of between $20.2 billion and $20.7 billion.



from Biotech News
Share:

Chinese Authorities Flood Markets With Cash to Try to Stem Selling

Chinese Authorities Flood Markets With Cash to Try to Stem Selling


Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 9+ You may proceed to the site by clicking here , however some pages might not work correctly.



from Biotech News
Share:

Cytokinetics, Inc. (CYTK) Downgraded to Hold at Zacks Investment Research

Cytokinetics, Inc. (CYTK) Downgraded to Hold at Zacks Investment Research


According to Zacks, "Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility.



from Biotech News
Share:

AJHP Reveals Extensive Redesign with January 15 Issue

AJHP Reveals Extensive Redesign with January 15 Issue


With its January 15, 2016, issue, AJHP is launching a new design to signal the turning of a page and a new era for ASHP’s peer-reviewed, scholarly publication. The redesign of AJHP highlights the editors’ new approach to content – with theme issues, increased calls for papers on cutting-edge topics, an enhanced digital experience, an increased focus on ambulatory care, and a heavier emphasis on editorials that tackle the most difficult issues in healthcare. The new design also reflects a major change in AJHP’s mission – “Advancing Science, Pharmacy Practice, and Health Outcomes.” This broader focus supports AJHP’s role as a source of the latest scientific evidence, practice information, news, and opinion pieces that can guide medication use and healthcare delivery at the patient, population, and policy levels. “Over the course of its 72-year history, AJHP has been a repository for landmark publications, building a scholarly culture of excellence that has served patients and the profession well,” says AJHP Editor in Chief Daniel J. Cobaugh, Pharm.D., DABAT, FAACT. “The new design signifies the Journal’s continuing evolution as a relevant, high-impact, innovative, reader-and-author-friendly, 21st-century biomedical publication.” In addition to the complete redesign of the publication, the AJHP editors are pursuing editorials that will contemplate complex topics, pose difficult questions, and envision a better future for patients. These editorials will play a critical role as AJHP tackles the most difficult issues in modern healthcare. In 2015, there were editorials on pharmacists as second victims of medical errors, a patient-centric approach to specialty pharmacy practice, and opposition to pharmacists’ participation in capital punishment.Theme Issues To ensure that AJHP content is supporting members’ and other readers’ efforts to provide optimal patient care, AJHP will create two to four theme issues annually. These theme issues will address some of the most relevant topics confronting healthcare and the profession of pharmacy, with distinguished and respected pharmacists serving as guest editors. Guest editors Kevin Colgan, M.A., FASHP, and Phillip Empey, Pharm.D., Ph.D., BCPS, have already recruited author teams for upcoming theme issues on specialty pharmacy and precision medicine, respectively. Reduced Print Issues Beginning in 2016, AJHP is publishing two fewer print issues per year (eliminating the January 1 and May 1 issues), while still producing all issues for online consumption. Readers will continue to receive all 24 issues online each year, along with 22 print issues. The publishing of two fewer print issues allows AJHP to pursue not only the theme issues, but also the robust and dynamic redesign of the journal that will be revealed in the January 15 issue. Enhanced Digital ExperienceAJHP’s advances will continue in 2016 with the incorporation of the new AJHP design in the online version of the Journal. Readers will also notice additional upgrades, including the availability of PubMed-indexed, ahead-of-print articles and easier access to the AJHP Voices podcasts. Further transformation of the Journal’s digital presence will be under development over the next several months to provide a more dynamic reader experience and heighten the Journal’s impact. About ASHPASHP represents pharmacists who serve as patient care providers in acute and ambulatory settings. The organization’s more than 43,000 members include pharmacists, student pharmacists, and pharmacy technicians. For over 70 years, ASHP has been at the forefront of efforts to improve medication use and enhance patient safety. For more information about the wide array of ASHP activities and the many ways in which pharmacists advance healthcare, visit ASHP’s website, www.ashp.org, or its consumer website, http://ift.tt/1oqARdt.

from ASHP Health-System Pharmacy Press Releases and Announcements
Share:

Heart Failure Related Deaths on the Rise

Heart Failure Related Deaths on the Rise


Since the year 2000 the number of heart failure related deaths in this country has been going up steadily. But new reports by the Centers for Disease Control and Prevention show that numbers are climbing even faster.



from Biotech News
Share:

Frutarom invests in algae startup for food, cosmetic products

Frutarom invests in algae startup for food, cosmetic products


One of the world's largest flavoring and specialty natural ingredient companies is investing in algae to enhance its food and cosmetic products. Frutarom Industries said on Monday it bought half of a biotech startup called Algalo, which is based on a kibbutz, or communal farm, in northern Israel, that developed a way to efficiently cultivate, harvest and process a variety of algae.



from Biotech News
Share:

Press release distribution, EDGAR filing, XBRL, regulatory filings

Press release distribution, EDGAR filing, XBRL, regulatory filings


Gilead kondigt een aanduiding voor Prioritair Overzicht door de Amerikaanse FDA aan voor sofosbuvir/velpatasvir voor de behandeling van alle genotypen van chronische hepatitis C )--Gilead Sciences, Inc. heeft vandaag bekendgemaakt dat de U.S. Food and Drug Administration het bedrijf een Prioritair Overzicht heeft ... )--Tortoise Energy Infrastructure Corp. today announced that as of Dec. 31, 2015, the company's unaudited total assets were approximately $2.6 billion and i... Tortoise Pipeline & Energy Fund, Inc. Provides Unaudited Balance Sheet Information and Asset Coverage Ratio Update as of Dec. 31, 2015 )--Tortoise Pipeline & Energy Fund, Inc. today announced that as of Dec. 31, 2015, the company's unaudited total assets were approximately $241.5 millio... )--Square Panda teams up with the Andre Agassi Foundation for Education to launch groundbreaking reading readiness technology, and ... (more)



from Biotech News
Share:

Zacks Investment Research Upgrades Shire PLC (SHPG) to "Hold"

Zacks Investment Research Upgrades Shire PLC (SHPG) to "Hold"


According to Zacks, "Shire's third-quarter results were impressive with the company beating on both top- and bottom-line estimates. It holds a strong position in the ADHD market driven by Vyvanse.



from Biotech News
Share:

Gilead, Other Biotechs Selling Off On Market Weakness

Gilead, Other Biotechs Selling Off On Market Weakness


Market mayhem continues, as Gilead Sciences, Inc. and other biotech companies are selling off on Monday's market weakness. Gilead Science's weekly performance is hovering around -5.75 percent and the issue has a YTD performance of -3.5 percent.



from Biotech News
Share:

Eli Lilly and Co (LLY) Earns "Buy" Rating from Jefferies Group

Eli Lilly and Co (LLY) Earns "Buy" Rating from Jefferies Group


's stock had its "buy" rating restated by equities researchers at Jefferies Group in a research report issued on Monday, ARN reports. They currently have a $125.00 price objective on the stock.



from Biotech News
Share:

3 Must Own Biotech Stocks In 2016

3 Must Own Biotech Stocks In 2016


Last year I provided three of my top biotech selections for 2015 in January. Two of which had spectacular returns in the year just passed.



from Biotech News
Share:

Teva, Active Biotech halt higher doses of oral MS drug in trials

Teva, Active Biotech halt higher doses of oral MS drug in trials


Teva Pharmaceutical Industries and Active Biotech will discontinue higher doses of their oral drug in development for multiple sclerosis in two trials, citing the occurrence of non-fatal cardiovascular events in eight patients. Both trials of laquinimod will continue with the lower dose of 0.6 mg daily where there were no issues.



from Biotech News
Share:

Pfizer: A Dividend Growth Case Study

Pfizer: A Dividend Growth Case Study


Detractors of dividend growth always like to point at past darlings that eliminated or slashed dividends to convince themselves and the others that dividend growth is not all that it is made out to be. You know what.



from Biotech News
Share:

Navidea Biopharmaceuticals to Present at Biotech Showcase 2016

Navidea Biopharmaceuticals to Present at Biotech Showcase 2016


A live webcast of Mr. Gonzalez's Biotech Showcase presentation can be accessed at the following URL: http://ift.tt/1PG6OvL . An archived version of the webcast will be available two hours following the presentation and can be accessed within the Investors' section of the Navidea website at www.navidea.com .



from Biotech News
Share:

Enterovirus D68 linked to illegal immigration is behind fatal...

Enterovirus D68 linked to illegal immigration is behind fatal...


A strange virus that began to spread rapidly after multiple waves of illegal immigrant children were shipped into the U.S. from Latin America last year has been shown in a new study to be directly related to the "polio-like illness" that's reportedly infected at least 112 children in 34 states, and killed nearly a dozen others. Known as enterovirus D68, or EV-D68, the mystery virus picked up speed dramatically last fall, with the U.S. Centers for Disease Control and Prevention reporting that the number of new cases reported in 2014 was significantly higher than in any previous recorded year.



from Biotech News
Share:

AstraZeneca plc (AZN) Receives "Buy" Rating from Jefferies Group

AstraZeneca plc (AZN) Receives "Buy" Rating from Jefferies Group


's stock had its "buy" rating reiterated by Jefferies Group in a note issued to investors on Thursday, ARN reports. They currently have a GBX 5,600 target price on the biopharmaceutical company's stock.



from Biotech News
Share:

Valeant Pharmaceuticals Intl's (VRX) "Hold" Rating Reaffirmed at Mizuho

Valeant Pharmaceuticals Intl's (VRX) "Hold" Rating Reaffirmed at Mizuho


's stock had its "hold" rating reaffirmed by analysts at Mizuho in a research report issued on Sunday, Market Beat reports. An institutional investor recently raised its position in Valeant Pharmaceuticals Intl stock.



from Biotech News
Share:

Biogen Inc (BIIB) Rating Increased to Overweight at Piper Jaffray

Biogen Inc (BIIB) Rating Increased to Overweight at Piper Jaffray


In related news, CMO Alfred Sandrock sold 441 shares of the business's stock in a transaction that occurred on Friday, December 4th. The stock was sold at an average price of $277.00, for a total transaction of $122,157.00.



from Biotech News
Share: